je.st
news
Tag: update merck
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference
2014-01-13 14:35:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the companys anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Mercks Animal Health and Consumer Care businesses in the companys strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014. Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value in non-core areas of its business. Language: English Contact: MerckMedia:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461Investor:Carol Ferguson, 908-500-1101Justin Holko, 908-423- 5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
growth
annual
conference
Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices
2013-10-24 16:27:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the companys investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Imraan Munshi, (215) 652-0059Investor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
committee
practices
advisory
Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine
2013-05-23 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Mercks investigational adenosine A2A receptor antagonist for the treatment of Parkinsons disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. Language: English Contact HTML: MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: program
iii
update
medicine
Merck Provides Update on IMPROVE-IT Trial
2013-03-12 13:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT trial has completed its planned review of study data and recommended that the study continue. The study design calls for the collection of 5,250 clinical endpoints. Merck remains blinded to the actual results of this analysis and to other IMPROVE-IT safety and efficacy data. Language: English Contact HTML: MerckMedia:Kelley Dougherty, 908-423-4291Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
trial
merck
update merck
Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)
2013-01-11 13:39:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE (extended-release niacin/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Language: English Contact HTML: MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
steps
merck
extendedrelease